2Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia : mechanism of action, efficacy and tolerability. Drugs, 2008; 68 (16): 2269-2292.
3Fowler JA, Bettinger TL, Argo TR. Paliperidone extended - release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther. 2008; 50 (2): 231-248.
4Lieberman JA. Dopamine partial agonists : a new class of antipsychotic. CNS Drugs, 2004; 18 (4) : 251 -267.
5Citrome L. Palipcridone: quo vadis? Int J Clin Pract. 2007; 61 (4) : 653 -662.
6Thyssen A, Crauwels H, Clcton A, et al. Effects of hepatic impairment on the pharmacokinefics ofimmediaterelease paliperidone [poster]. 46th Annual Meeting of the NCEDU ; 2006; Boca Raton (FL), 186.
7Aravagiri M, Marder SR, Nuechterlein KH, et al. lntra - and interindividual variations in steady - state plasma concentrations of risperidone and 9 - hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003 ; 25 (6) : 657 - 664.
8Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9 - hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000; 22 (4) : 481 -485.
9Herbert Y, Melter MD, William V, et al. Efficacy and tolembility of oral pailiperidone extcnded - releaase tablets in the treatment of acute schizophrenia: pooled data from three 6- week, placebocontrolled studies. J Clin Psychiatry, 2008 ; 69 (5): 817-829.
10Marino J, Caballero J. Paliperidone extended - release for the treatment of schizophrenia. Pharmacotherapy, 2008 ; 28 (10): 1283 -1298.
2LEYSEN JE, JANSSEN PM, MEGENS AA, et al. Risperidone: a novel antipsychotic with balanced serotonindopamine antagonism, receptor occupancy profile, and pharmacologic activity [ J ]. J Clln Psychiatry, 1994, 55 ( Suppl 1 ) : S5 - S12.
3RICHELSON E, SOUDER T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds [ J ]. Life Sci, 2000, 68 ( 1 ) : 29 - 39.
4DOLDER C, NELSON M, DEYO Z. Paliperidone for schizophre- nia[ J]. Am J Health Syst Pharm, 2008, 65 (5) : 403 -413.
5SCHNEIDER RA, LIZER MH. Apparent seizure and atrial fibril- lation associated with paliperidone[ J]. Am J Health Syst Pharm, 2008, 65(22) : 2122 -2125.
6KANE J, CANAS F, KRAMER M, et al. Treatment of schizo- phrenia with paliperidone extended-release tablets: a 6-week pla- cebo-controlled trial [ J ]. Schizophr Res, 2007, 90 ( 1 - 3 ) : 147 - 161.
7KRAMER M, SIMPSON G, MACIULIS V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, place- bo-controlledstudy[J]. J Clin Psychopharmacol, 2007, 27 (1) : 6 - 14.
8DAVIDSON M, EMSLEY R, KRAMER M, et al. Efficacy, safety and early response of ( paliperidone ER) : results of a 6- week, randomized, placebo-controlled study[ J]. Schizophr Res, 2007, 96(1 -3): 273 -274.
9Collaborative Working Group on Clinical Trial Evaluations. Ad- verse effects of the atypical antipsyehoties. Collaborative Working Group on Clinical Trial Evaluations [ J ]. J Clin Psychiatry, 1998, 59(Suppl 12) :S17 - S22.
10SENGUL MC, KAYA K, YILMAZ A, et al. Pulmonary throm- boembolism due to paliperidone: report of 2 cases [ J ]. Am J Emerg Meal, 2014, 32(7) :814.
